Intelligence Feed event · Capital · 2026-08-04

    Supernus and Indivior Announce All-Stock Merger to Create Pharma Leader

    Question

    Supernus and Indivior Announce All-Stock Merger to Create Pharma Leader

    Direct answer

    The merger combines two significant players in the CNS and addiction treatment markets. The $125 million in synergies is expected to be reinvested into the combined R&D pipeline. Investor caution may stem from the all-stock nature of the deal and potential integration risks.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Supernus and Indivior Announce All-Stock Merger to Create Pharma Leader”, revision 1, evidence through 2026-08-04. https://marketontology.com/market-events/2026-08-04/supernus-and-indivior-announce-all-stock-merger-to-create-pharma-leader-ef42de

    CAPITAL
    Supernus and Indivior Announce All-Stock Merger to Create Pharma Leader
    The merger combines two significant players in the CNS and addiction treatment markets. The $125 million in synergies is expected to be reinvested into the combined R&D pipeline. Investor caution may stem from the all-stock nature of the deal and potential integration risks.
    SUPNINDV
    Impact
    65
    AUG 4
    SIG
    90%
    SUPNINDV
    Supernus and Indivior Announce All-Stock Merger to Create Pharma Leader
    The merger combines two significant players in the CNS and addiction treatment markets. The $125 million in synergies is expected to be reinvested into the combined R&D pipeline. Investor caution may stem from the all-stock nature of the deal and potential integration risks.
    → Consolidation in mid-cap pharma to improve R&D efficiency and scale.
    Impact
    The merger combines two significant players in the CNS and addiction treatment markets. The $125 million in synergies is expected to be reinvested into the combined R&D pipeline. Investor caution may stem from the all-stock nature of the deal and potential integration risks.
    Affected
    SUPNINDV
    Transmission
    Consolidation in mid-cap pharma to improve R&D efficiency and scale.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month